Multimodal imaging of DIP-joint and SEC can help distinguish PsA from psoriasis or OAApril 27, 2022Psoriatic Arthritis
Long-term efficacy, safety data for ixekizumab in pediatric psoriasis reportedApril 25, 2022Psoriatic Arthritis
Secukinumab’s antipsoriatic effects confirmed in U.S. patient populationApril 25, 2022Psoriatic Arthritis
Fluorescence optical imaging holds potential for detecting early signs of PsAApril 25, 2022Psoriatic Arthritis
Guselkumab reduces collagen degradation biomarker levels associated with active PsAApril 25, 2022Psoriatic Arthritis
Large integrated safety analysis reinforces known safety profile of ixekizumab in PsAApril 25, 2022Psoriatic Arthritis
Multimodal imaging of DIP-joint and SEC can help distinguish PsA from psoriasis or OAApril 25, 2022Psoriatic Arthritis
Differential response to ixekizumab among males and females with PsAApril 25, 2022Psoriatic Arthritis
Robust and sustained improvement with guselkumab in a diverse population of patients with PsAApril 25, 2022Psoriatic Arthritis
IL-17 inhibitors associated with higher treatment persistence in PsAApril 25, 2022Psoriatic Arthritis
Hypocaloric diet controls joint activity in psoriatic arthritis – regardless of weight lossApril 14, 2022Psoriatic Arthritis
